P&G Health Launches First APAC Pharmacist Guidelines for Peripheral Neuropathy Management

Key Takeaways

• First-ever Asia-Pacific guidelines empower community pharmacists to identify, assess, and manage peripheral neuropathy
• Guidelines address critical healthcare gap affecting 50% of diabetics and 10% of adults in the region
• Initiative positions community pharmacists as first-line healthcare contact for early intervention and improved patient outcomes

---

P&G Health Partners with APAC Experts to Launch Groundbreaking Peripheral Neuropathy Guidelines

Leading Asia-Pacific pharmacist experts, in collaboration with P&G Health, announced the region’s first comprehensive guideline designed specifically for community pharmacists to identify, assess, and manage peripheral neuropathy on April 16, 2026, in Singapore.

Addressing a Critical Healthcare Gap

The new guidelines tackle a significant medical challenge affecting millions across the Asia-Pacific region. Current statistics reveal that 1 in 2 diabetics and 1 in 10 adults suffer from peripheral neuropathy, a condition that causes pain, numbness, and weakness in hands and feet due to nerve damage.

Elevating Community Pharmacy Standards

The initiative recognizes community pharmacists as the most accessible point of healthcare contact for patients, positioning them as crucial frontline healthcare providers. These evidence-based guidelines provide standardized protocols for:

• Early identification of peripheral neuropathy symptoms
• Comprehensive patient assessment techniques
• Appropriate management strategies and referral protocols
• Patient education and counseling approaches

Market Impact and Healthcare Transformation

This collaborative effort represents a significant shift in healthcare delivery across the Asia-Pacific region. By empowering community pharmacists with specialized knowledge and standardized protocols, the guidelines aim to:

• Improve early detection rates of peripheral neuropathy
• Reduce healthcare system burden through community-level intervention
• Enhance patient outcomes through accessible, consistent care
• Establish new standards for pharmacist-led chronic condition management

Regional Healthcare Innovation

The partnership between P&G Health and regional pharmacy experts demonstrates the pharmaceutical industry’s commitment to expanding healthcare access beyond traditional clinical settings. This initiative could serve as a model for addressing other chronic conditions through community pharmacy networks across emerging markets.

---

Frequently Asked Questions

What does this mean for patients with peripheral neuropathy?

Patients will have improved access to early detection and management of peripheral neuropathy through their local community pharmacists, who will now follow standardized assessment and care protocols.

When will these guidelines be implemented across APAC pharmacies?

The guidelines were announced in April 2026, with implementation timelines likely varying by country as local pharmacy associations and regulatory bodies adopt the recommendations.

How do these guidelines compare to existing peripheral neuropathy treatments?

These guidelines don’t replace existing treatments but rather establish standardized protocols for community pharmacists to identify, assess, and appropriately refer or manage patients, filling a gap in accessible healthcare delivery.